Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-11-17

AUTHORS

Melissa Pavilack, Robert A. Clifford, Tara Gonzales, Amanda M. Kong, Sally Wade, Kimmie K. McLaurin

ABSTRACT

INTRODUCTION: Palivizumab is indicated for the prevention of respiratory syncytial virus (RSV) infection in high-risk children. Previous palivizumab utilization studies examined prior authorization claims but did not examine utilization within insured populations as a whole. This study describes outpatient palivizumab utilization trends and characterizes high-risk infants receiving palivizumab within Medicaid- and commercially insured populations. METHODS: Infants born July 1, 2003 through June 30, 2013 were identified in the MarketScan® Multistate Medicaid and Commercial claims databases. Infants with ≥ 18 months of continuous medical insurance enrollment with pharmacy benefits after birth and evidence of chronic lung disease of prematurity (CLDP), congenital heart disease (CHD), or preterm birth without CLDP or CHD were studied. Palivizumab use and demographic and clinical characteristics were measured in infant subgroups. Outpatient palivizumab utilization rates were calculated for each seasonal year (July-June) and for each infant subgroup. RESULTS: In total, 29,350 (2.1%) Medicaid-insured and 9589 (2.5%) commercially insured infants received palivizumab and had CLDP, CHD, or were born at < 37 weeks gestational age (wGA). Infants with CLDP (82%) and those < 29 wGA (78%) had the highest utilization. Decreases in utilization rates between the 2003-2004 and 2012-2013 seasons were seen among Medicaid-insured infants born at 29-36 wGA (all P < .0001), and commercially insured infants born at 31-32 wGA (P < .0001), 33-34 wGA (P = .055), 35-36 wGA (P < .0001), and with CHD (P = .003). Utilization by month was consistent across subgroups among Medicaid- and commercially insured infants, with most doses administered from November to March. CONCLUSION: Palivizumab use is targeted to a small percentage of infants who are at highest risk of hospitalization for RSV disease. Utilization declined in recent years in both Medicaid- and commercially insured infant groups. Most palivizumab doses were administered from November to March, with most infants receiving ≤ 5 doses. FUNDING: AstraZeneca. More... »

PAGES

121-134

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40121-017-0178-6

DOI

http://dx.doi.org/10.1007/s40121-017-0178-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1092753962

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29149439


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1114", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Paediatrics and Reproductive Medicine", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "AstraZeneca, Gaithersburg, MD USA", 
          "id": "http://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "AstraZeneca, Gaithersburg, MD USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pavilack", 
        "givenName": "Melissa", 
        "id": "sg:person.014104653547.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014104653547.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Coastal Pediatric Associates, Charleston, SC USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Coastal Pediatric Associates, Charleston, SC USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Clifford", 
        "givenName": "Robert A.", 
        "id": "sg:person.015261200302.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015261200302.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca, Gaithersburg, MD USA", 
          "id": "http://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "AstraZeneca, Gaithersburg, MD USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gonzales", 
        "givenName": "Tara", 
        "id": "sg:person.012420313507.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012420313507.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Truven Health Analytics, an IBM Company, Cambridge, MA USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Truven Health Analytics, an IBM Company, Cambridge, MA USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kong", 
        "givenName": "Amanda M.", 
        "id": "sg:person.011053751617.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011053751617.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Wade Outcomes Research and Consulting, Salt Lake City, UT USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Wade Outcomes Research and Consulting, Salt Lake City, UT USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wade", 
        "givenName": "Sally", 
        "id": "sg:person.0617012057.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617012057.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca, Gaithersburg, MD USA", 
          "id": "http://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "AstraZeneca, Gaithersburg, MD USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McLaurin", 
        "givenName": "Kimmie K.", 
        "id": "sg:person.01116472424.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116472424.97"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/1471-2334-13-334", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052925587", 
          "https://doi.org/10.1186/1471-2334-13-334"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-11-17", 
    "datePublishedReg": "2017-11-17", 
    "description": "INTRODUCTION: Palivizumab is indicated for the prevention of respiratory syncytial virus (RSV) infection in high-risk children. Previous palivizumab utilization studies examined prior authorization claims but did not examine utilization within insured populations as a whole. This study describes outpatient palivizumab utilization trends and characterizes high-risk infants receiving palivizumab within Medicaid- and commercially insured populations.\nMETHODS: Infants born July 1, 2003 through June 30, 2013 were identified in the MarketScan\u00ae Multistate Medicaid and Commercial claims databases. Infants with\u00a0\u2265\u00a018\u00a0months of continuous medical insurance enrollment with pharmacy benefits after birth and evidence of chronic lung disease of prematurity (CLDP), congenital heart disease (CHD), or preterm birth without CLDP or CHD were studied. Palivizumab use and demographic and clinical characteristics were measured in infant subgroups. Outpatient palivizumab utilization rates were calculated for each seasonal year (July-June) and for each infant subgroup.\nRESULTS: In total, 29,350 (2.1%) Medicaid-insured and 9589 (2.5%) commercially insured infants received palivizumab and had CLDP, CHD, or were born at\u00a0<\u00a037\u00a0weeks gestational age (wGA). Infants with CLDP (82%) and those\u00a0<\u00a029 wGA (78%) had the highest utilization. Decreases in utilization rates between the 2003-2004 and 2012-2013 seasons were seen among Medicaid-insured infants born at 29-36 wGA (all P\u00a0<\u00a0.0001), and commercially insured infants born at 31-32 wGA (P\u00a0<\u00a0.0001), 33-34 wGA (P\u00a0=\u00a0.055), 35-36 wGA (P\u00a0<\u00a0.0001), and with CHD (P\u00a0=\u00a0.003). Utilization by month was consistent across subgroups among Medicaid- and commercially insured infants, with most doses administered from November to March.\nCONCLUSION: Palivizumab use is targeted to a small percentage of infants who are at highest risk of hospitalization for RSV disease. Utilization declined in recent years in both Medicaid- and commercially insured infant groups. Most palivizumab doses were administered from November to March, with most infants receiving\u00a0\u2264\u00a05 doses.\nFUNDING: AstraZeneca.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40121-017-0178-6", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1050275", 
        "issn": [
          "2193-8229", 
          "2193-6382"
        ], 
        "name": "Infectious Diseases and Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "7"
      }
    ], 
    "keywords": [
      "weeks gestational age", 
      "congenital heart disease", 
      "palivizumab use", 
      "infant subgroups", 
      "respiratory syncytial virus infection", 
      "respiratory syncytial virus prophylaxis", 
      "syncytial virus infection", 
      "chronic lung disease", 
      "high-risk infants", 
      "high-risk children", 
      "multistate Medicaid", 
      "palivizumab doses", 
      "RSV disease", 
      "clinical characteristics", 
      "virus prophylaxis", 
      "preterm birth", 
      "gestational age", 
      "lung disease", 
      "most infants", 
      "heart disease", 
      "virus infection", 
      "infant group", 
      "high risk", 
      "palivizumab", 
      "insured population", 
      "most doses", 
      "utilization studies", 
      "infants", 
      "pharmacy benefits", 
      "utilization trends", 
      "Medicaid", 
      "insurance enrollment", 
      "disease", 
      "doses", 
      "subgroups", 
      "months", 
      "birth", 
      "small percentage", 
      "utilization rate", 
      "MarketScan", 
      "prophylaxis", 
      "hospitalization", 
      "prematurity", 
      "population", 
      "years", 
      "infection", 
      "prevention", 
      "age", 
      "enrollment", 
      "total", 
      "risk", 
      "children", 
      "AstraZeneca", 
      "LT", 
      "study", 
      "CLDP", 
      "seasonal year", 
      "rate", 
      "high utilization", 
      "group", 
      "percentage", 
      "use", 
      "utilization", 
      "evidence", 
      "decrease", 
      "database", 
      "benefits", 
      "recent years", 
      "trends", 
      "Commercially", 
      "characteristics", 
      "whole", 
      "claims", 
      "commercial", 
      "season", 
      "Previous palivizumab utilization studies", 
      "palivizumab utilization studies", 
      "prior authorization claims", 
      "authorization claims", 
      "outpatient palivizumab utilization trends", 
      "palivizumab utilization trends", 
      "continuous medical insurance enrollment", 
      "medical insurance enrollment", 
      "Outpatient palivizumab utilization rates", 
      "palivizumab utilization rates", 
      "Most palivizumab doses", 
      "Outpatient Respiratory Syncytial Virus Prophylaxis", 
      "Syncytial Virus Prophylaxis"
    ], 
    "name": "Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants", 
    "pagination": "121-134", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1092753962"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40121-017-0178-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29149439"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40121-017-0178-6", 
      "https://app.dimensions.ai/details/publication/pub.1092753962"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:46", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_740.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40121-017-0178-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40121-017-0178-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40121-017-0178-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40121-017-0178-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40121-017-0178-6'


 

This table displays all metadata directly associated to this object as RDF triples.

196 TRIPLES      22 PREDICATES      115 URIs      106 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40121-017-0178-6 schema:about anzsrc-for:11
2 anzsrc-for:1114
3 schema:author N003de4a791df4d54b3607b75874c6e4e
4 schema:citation sg:pub.10.1186/1471-2334-13-334
5 schema:datePublished 2017-11-17
6 schema:datePublishedReg 2017-11-17
7 schema:description INTRODUCTION: Palivizumab is indicated for the prevention of respiratory syncytial virus (RSV) infection in high-risk children. Previous palivizumab utilization studies examined prior authorization claims but did not examine utilization within insured populations as a whole. This study describes outpatient palivizumab utilization trends and characterizes high-risk infants receiving palivizumab within Medicaid- and commercially insured populations. METHODS: Infants born July 1, 2003 through June 30, 2013 were identified in the MarketScan<sup>®</sup> Multistate Medicaid and Commercial claims databases. Infants with ≥ 18 months of continuous medical insurance enrollment with pharmacy benefits after birth and evidence of chronic lung disease of prematurity (CLDP), congenital heart disease (CHD), or preterm birth without CLDP or CHD were studied. Palivizumab use and demographic and clinical characteristics were measured in infant subgroups. Outpatient palivizumab utilization rates were calculated for each seasonal year (July-June) and for each infant subgroup. RESULTS: In total, 29,350 (2.1%) Medicaid-insured and 9589 (2.5%) commercially insured infants received palivizumab and had CLDP, CHD, or were born at &lt; 37 weeks gestational age (wGA). Infants with CLDP (82%) and those &lt; 29 wGA (78%) had the highest utilization. Decreases in utilization rates between the 2003-2004 and 2012-2013 seasons were seen among Medicaid-insured infants born at 29-36 wGA (all P &lt; .0001), and commercially insured infants born at 31-32 wGA (P &lt; .0001), 33-34 wGA (P = .055), 35-36 wGA (P &lt; .0001), and with CHD (P = .003). Utilization by month was consistent across subgroups among Medicaid- and commercially insured infants, with most doses administered from November to March. CONCLUSION: Palivizumab use is targeted to a small percentage of infants who are at highest risk of hospitalization for RSV disease. Utilization declined in recent years in both Medicaid- and commercially insured infant groups. Most palivizumab doses were administered from November to March, with most infants receiving ≤ 5 doses. FUNDING: AstraZeneca.
8 schema:genre article
9 schema:inLanguage en
10 schema:isAccessibleForFree true
11 schema:isPartOf N91cb3c2c58834e6087b7ff6159748404
12 Ndb4c50c7548644d7ad06d0764c43d3fb
13 sg:journal.1050275
14 schema:keywords AstraZeneca
15 CLDP
16 Commercially
17 LT
18 MarketScan
19 Medicaid
20 Most palivizumab doses
21 Outpatient Respiratory Syncytial Virus Prophylaxis
22 Outpatient palivizumab utilization rates
23 Previous palivizumab utilization studies
24 RSV disease
25 Syncytial Virus Prophylaxis
26 age
27 authorization claims
28 benefits
29 birth
30 characteristics
31 children
32 chronic lung disease
33 claims
34 clinical characteristics
35 commercial
36 congenital heart disease
37 continuous medical insurance enrollment
38 database
39 decrease
40 disease
41 doses
42 enrollment
43 evidence
44 gestational age
45 group
46 heart disease
47 high risk
48 high utilization
49 high-risk children
50 high-risk infants
51 hospitalization
52 infant group
53 infant subgroups
54 infants
55 infection
56 insurance enrollment
57 insured population
58 lung disease
59 medical insurance enrollment
60 months
61 most doses
62 most infants
63 multistate Medicaid
64 outpatient palivizumab utilization trends
65 palivizumab
66 palivizumab doses
67 palivizumab use
68 palivizumab utilization rates
69 palivizumab utilization studies
70 palivizumab utilization trends
71 percentage
72 pharmacy benefits
73 population
74 prematurity
75 preterm birth
76 prevention
77 prior authorization claims
78 prophylaxis
79 rate
80 recent years
81 respiratory syncytial virus infection
82 respiratory syncytial virus prophylaxis
83 risk
84 season
85 seasonal year
86 small percentage
87 study
88 subgroups
89 syncytial virus infection
90 total
91 trends
92 use
93 utilization
94 utilization rate
95 utilization studies
96 utilization trends
97 virus infection
98 virus prophylaxis
99 weeks gestational age
100 whole
101 years
102 schema:name Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants
103 schema:pagination 121-134
104 schema:productId N1959f06fecd9461a94229830589363ea
105 N7b5cddca464c44638cbea65a25f386d6
106 Ncf33a8879587441e93fc8b8d738f27d5
107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092753962
108 https://doi.org/10.1007/s40121-017-0178-6
109 schema:sdDatePublished 2022-01-01T18:46
110 schema:sdLicense https://scigraph.springernature.com/explorer/license/
111 schema:sdPublisher N03437cf401274c7192777bdee6c5cf90
112 schema:url https://doi.org/10.1007/s40121-017-0178-6
113 sgo:license sg:explorer/license/
114 sgo:sdDataset articles
115 rdf:type schema:ScholarlyArticle
116 N003de4a791df4d54b3607b75874c6e4e rdf:first sg:person.014104653547.84
117 rdf:rest Na2edd3fa1f0941bc98b0e5ee8eb9b1fd
118 N03437cf401274c7192777bdee6c5cf90 schema:name Springer Nature - SN SciGraph project
119 rdf:type schema:Organization
120 N155e48c6ae08445682e98ce4761c9f7f rdf:first sg:person.0617012057.00
121 rdf:rest Neb2b7156eefa48648e070cf8328bfab0
122 N1959f06fecd9461a94229830589363ea schema:name pubmed_id
123 schema:value 29149439
124 rdf:type schema:PropertyValue
125 N7b5cddca464c44638cbea65a25f386d6 schema:name doi
126 schema:value 10.1007/s40121-017-0178-6
127 rdf:type schema:PropertyValue
128 N91cb3c2c58834e6087b7ff6159748404 schema:volumeNumber 7
129 rdf:type schema:PublicationVolume
130 Na2edd3fa1f0941bc98b0e5ee8eb9b1fd rdf:first sg:person.015261200302.08
131 rdf:rest Nc15e7b17355445f4879701494917829c
132 Nc15e7b17355445f4879701494917829c rdf:first sg:person.012420313507.14
133 rdf:rest Nf8d7148d64ad4c73990c12a94c2309de
134 Ncf33a8879587441e93fc8b8d738f27d5 schema:name dimensions_id
135 schema:value pub.1092753962
136 rdf:type schema:PropertyValue
137 Ndb4c50c7548644d7ad06d0764c43d3fb schema:issueNumber 1
138 rdf:type schema:PublicationIssue
139 Neb2b7156eefa48648e070cf8328bfab0 rdf:first sg:person.01116472424.97
140 rdf:rest rdf:nil
141 Nf8d7148d64ad4c73990c12a94c2309de rdf:first sg:person.011053751617.55
142 rdf:rest N155e48c6ae08445682e98ce4761c9f7f
143 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
144 schema:name Medical and Health Sciences
145 rdf:type schema:DefinedTerm
146 anzsrc-for:1114 schema:inDefinedTermSet anzsrc-for:
147 schema:name Paediatrics and Reproductive Medicine
148 rdf:type schema:DefinedTerm
149 sg:journal.1050275 schema:issn 2193-6382
150 2193-8229
151 schema:name Infectious Diseases and Therapy
152 schema:publisher Springer Nature
153 rdf:type schema:Periodical
154 sg:person.011053751617.55 schema:affiliation grid-institutes:None
155 schema:familyName Kong
156 schema:givenName Amanda M.
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011053751617.55
158 rdf:type schema:Person
159 sg:person.01116472424.97 schema:affiliation grid-institutes:grid.418152.b
160 schema:familyName McLaurin
161 schema:givenName Kimmie K.
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116472424.97
163 rdf:type schema:Person
164 sg:person.012420313507.14 schema:affiliation grid-institutes:grid.418152.b
165 schema:familyName Gonzales
166 schema:givenName Tara
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012420313507.14
168 rdf:type schema:Person
169 sg:person.014104653547.84 schema:affiliation grid-institutes:grid.418152.b
170 schema:familyName Pavilack
171 schema:givenName Melissa
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014104653547.84
173 rdf:type schema:Person
174 sg:person.015261200302.08 schema:affiliation grid-institutes:None
175 schema:familyName Clifford
176 schema:givenName Robert A.
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015261200302.08
178 rdf:type schema:Person
179 sg:person.0617012057.00 schema:affiliation grid-institutes:None
180 schema:familyName Wade
181 schema:givenName Sally
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617012057.00
183 rdf:type schema:Person
184 sg:pub.10.1186/1471-2334-13-334 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052925587
185 https://doi.org/10.1186/1471-2334-13-334
186 rdf:type schema:CreativeWork
187 grid-institutes:None schema:alternateName Coastal Pediatric Associates, Charleston, SC USA
188 Truven Health Analytics, an IBM Company, Cambridge, MA USA
189 Wade Outcomes Research and Consulting, Salt Lake City, UT USA
190 schema:name Coastal Pediatric Associates, Charleston, SC USA
191 Truven Health Analytics, an IBM Company, Cambridge, MA USA
192 Wade Outcomes Research and Consulting, Salt Lake City, UT USA
193 rdf:type schema:Organization
194 grid-institutes:grid.418152.b schema:alternateName AstraZeneca, Gaithersburg, MD USA
195 schema:name AstraZeneca, Gaithersburg, MD USA
196 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...